Related Experiment Video
Updated: Aug 11, 2026

16:02
Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
Overcoming Difficult, Impossible, and Meaningless Animal Testing under REACH: Opportunities for Robust Chemical Risk
Martijn van Velthoven1, Giorgia Pallocca2, Vicente Aranda3
1VelTox Strategy Consultancy.
Regulatory Toxicology and Pharmacology : RTP
|August 9, 2026
Summary
The Animal-Free Safety Assessment (AFSA) initiative developed criteria to identify when animal testing is difficult, impossible, or meaningless (DIM) under EU REACH regulations. This promotes the use of non-animal testing methods for chemical safety assessments.
Area of Science:
- Chemical safety assessment
- Toxicology
- Regulatory science
Background:
- The European Union's REACH regulation promotes minimizing animal testing through mechanisms like data sharing and read-across.
- Despite existing frameworks, new animal studies are sometimes required even when they offer limited scientific or regulatory value.
- Translating REACH's flexibility for non-animal testing into consistent practice remains a challenge.
Purpose of the Study:
- To define scientific and procedural criteria for identifying "difficult, impossible, or meaningless" (DIM) animal testing scenarios within the EU REACH framework.
- To demonstrate how non-animal testing methods can effectively address information requirements in identified DIM cases.
- To propose recommendations for refining criteria and promoting non-animal approaches for chemical safety.
Main Methods:
- Development of specific scientific and procedural criteria by the Animal-Free Safety Assessment (AFSA) Collaboration to define DIM testing.
- Application of these DIM criteria to screen REACH registration dossiers for cases where animal testing may be unnecessary.
- Analysis of existing non-animal approaches to address information needs in identified DIM situations.
Main Results:
- Specific criteria were defined to identify situations where animal testing under REACH is difficult, impossible, or meaningless.
- The AFSA DIM initiative identified concrete scenarios where animal testing provides no added value.
- Existing non-animal methods were shown to be capable of addressing information needs in these identified cases.
Conclusions:
- Further refinement of DIM criteria is recommended for broader application to REACH endpoints, prioritizing human health.
- Adaptations to avoid DIM testing for human health endpoints should be evaluated.
- Increased focus on exposure-driven assessment within Next-Generation Risk Assessment (NGRA) is suggested for chemical safety evaluations.
Related Concept Videos
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

